Vitamin D deficiency worsens outcomes with B-cell lymphoma

August 27, 2014
Vitamin D deficiency worsens outcomes with B-cell lymphoma

(HealthDay)—Vitamin D deficiency (VDD) contributes to worse outcomes in elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, according to a study published online Aug. 18 in the Journal of Clinical Oncology.

Jörg Thomas Bittenbring, M.D., from Universitätsklinikum des Saarlandes in Germany, and colleagues examined the impact and mechanisms of VDD in patients with DLBCL. Chemoluminescent immunoassays were used to evaluate 359 pretreatment 25-hydroxyvitamin D3 serum levels from the RICOVER-60 study (Six Versus Eight Cycles of Biweekly CHOP-14 With or Without Rituximab) and 63 from the RICOVER-noRTh study (an amendment to the RICOVER-60 study).

The researchers found that RICOVER-60 patients treated with rituximab with VDD (≤8 ng/mL) had three-year event-free survival (EFS) of 59 percent and three-year overall survival (OS) of 70 percent, while those with vitamin D levels >8 ng/mL treated with rituximab had EFS and OS of 79 and 82 percent, respectively. In multivariate analysis adjusting for International Prognostic Index risk factors, these differences remained significant, with hazard ratios of 2.1 (P = 0.008) for EFS and 1.9 (P = 0.040) for OS. In all seven individuals with VDD, there were significant increases in rituximab-mediated cellular cytotoxicity (RMCC; P < 0.001) after substitution and normalization of their vitamin D levels.

"That VDD impairs RMCC and substitution improves RMCC strongly suggests that vitamin D substitution enhances efficacy," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: R-CHOP benefits older mantle-cell lymphoma patients

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

R-CHOP benefits older mantle-cell lymphoma patients

August 9, 2012

(HealthDay) -- In older patients with mantle-cell lymphoma, a rituximab-based chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) followed by maintenance therapy with rituximab ...

Biologic treatments for RA carry similar infection risk

July 28, 2014

(HealthDay)—The risk of hospitalized bacterial infections in older rheumatoid arthritis (RA) patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study ...

Vitamin D increases breast cancer patient survival

March 6, 2014

Breast cancer patients with high levels of vitamin D in their blood are twice as likely to survive the disease as women with low levels of this nutrient, report University of California, San Diego School of Medicine researchers ...

Recommended for you

How the nervous system controls tumor growth

March 22, 2017

(Medical Xpress)—From the time it first comes online during development the nervous system begins to exact precise control over many biologic functions. In some cases, too much control. When it does, a little nerve-squelching ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.